113 related articles for article (PubMed ID: 38717693)
1. Hepatic artery infusion chemotherapy combined with camrelizumab plus rivoceranib for hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter propensity score-matching analysis.
Li Y; Guo J; Liu W; Pang H; Song Y; Wu S; Zhang F; Yan D; Chen J; An C; Li C
Hepatol Int; 2024 May; ():. PubMed ID: 38717693
[TBL] [Abstract][Full Text] [Related]
2. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis.
Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Zhu LZ; Xu HF; Yang RJ
Biomed Res Int; 2021; 2021():6670367. PubMed ID: 34337041
[TBL] [Abstract][Full Text] [Related]
3. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Choi JH; Chung WJ; Bae SH; Song DS; Song MJ; Kim YS; Yim HJ; Jung YK; Suh SJ; Park JY; Kim DY; Kim SU; Cho SB
Cancer Chemother Pharmacol; 2018 Sep; 82(3):469-478. PubMed ID: 29982870
[TBL] [Abstract][Full Text] [Related]
4. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S; Chan SL; Gu S; Bai Y; Ren Z; Lin X; Chen Z; Jia W; Jin Y; Guo Y; Hu X; Meng Z; Liang J; Cheng Y; Xiong J; Ren H; Yang F; Li W; Chen Y; Zeng Y; Sultanbaev A; Pazgan-Simon M; Pisetska M; Melisi D; Ponomarenko D; Osypchuk Y; Sinielnikov I; Yang TS; Liang X; Chen C; Wang L; Cheng AL; Kaseb A; Vogel A;
Lancet; 2023 Sep; 402(10408):1133-1146. PubMed ID: 37499670
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis.
Ahn YE; Suh SJ; Yim HJ; Seo YS; Yoon EL; Kim TH; Lee YS; Yim SY; Kim HR; Kang SH; Jung YK; Kim JH; Yeon JE; Um SH; Byun KS
Gut Liver; 2021 Mar; 15(2):284-294. PubMed ID: 32307975
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial.
Zheng K; Zhu X; Fu S; Cao G; Li WQ; Xu L; Chen H; Wu D; Yang R; Wang K; Liu W; Wang H; Bao Q; Liu M; Hao C; Shen L; Xing B; Wang X
Radiology; 2022 May; 303(2):455-464. PubMed ID: 35103539
[TBL] [Abstract][Full Text] [Related]
7. Hepatic arterial infusion oxaliplatin plus raltitrexed and chemoembolization in hepatocellular carcinoma with portal vein invasion: A propensity score-matching cohort study.
Chen S; Yuan B; Yu W; Wang X; He C; Chen C
J Surg Oncol; 2022 Dec; 126(7):1205-1214. PubMed ID: 35856502
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of therapeutics effects of transcatheter arterial chemoembolization combined with iodine-125 seed implantation and sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis].
Luo J; Zheng JP; Shao GL; Wen S; Guo LW; Zeng H; Zhang L; Qian CY; Hao WY
Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):298-304. PubMed ID: 29996343
[No Abstract] [Full Text] [Related]
9. Efficacy and safety of transcatheter arterial chemoembolization plus hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis in the main trunk.
Wu Z; Gao J; Zhuang W; Yang J; Guo W
J Cancer Res Ther; 2022 Apr; 18(2):345-351. PubMed ID: 35645099
[TBL] [Abstract][Full Text] [Related]
10. Efficiency and safety of hepatic arterial infusion chemotherapy (HAIC) combined with anti-PD1 therapy versus HAIC monotherapy for advanced hepatocellular carcinoma: A multicenter propensity score matching analysis.
Li Y; Liu W; Chen J; Chen Y; Guo J; Pang H; Zhang W; An C; Li C
Cancer Med; 2024 Jan; 13(1):. PubMed ID: 38196277
[TBL] [Abstract][Full Text] [Related]
11. Modified Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab for Advanced HCC: Two Case Reports.
Tian Y; Jin W; Sun H; Jin D; Kang D; Li Z; Piao L
J Hepatocell Carcinoma; 2023; 10():1587-1593. PubMed ID: 37791067
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
Yuan G; Cheng X; Li Q; Zang M; Huang W; Fan W; Wu T; Ruan J; Dai W; Yu W; Chen M; Guo Y; Hu X; Chen J
Onco Targets Ther; 2020; 13():12683-12693. PubMed ID: 33328740
[TBL] [Abstract][Full Text] [Related]
13. Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis.
Liu M; Shi J; Mou T; Wang Y; Wu Z; Shen A
J Gastroenterol Hepatol; 2020 Aug; 35(8):1277-1287. PubMed ID: 32052876
[TBL] [Abstract][Full Text] [Related]
14. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
Fu Y; Peng W; Zhang W; Yang Z; Hu Z; Pang Y; Hu D; Chen J; Wang J; Zhou Z; Xu L; Chen M; Zhang Y
J Gastroenterol; 2023 Apr; 58(4):413-424. PubMed ID: 36894804
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and safety of multimodality treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: patient-level network meta-analysis.
Leung JH; Wang SY; Leung HWC; Chan ALF
Front Oncol; 2024; 14():1344798. PubMed ID: 38434681
[TBL] [Abstract][Full Text] [Related]
16. A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus.
Li X; Ding X; Liu M; Wang J; Sun W; Teng Y; Xu Y; Wu H; Li W; Zhou L; Chen J
Cancer Med; 2023 Aug; 12(16):16805-16814. PubMed ID: 37387602
[TBL] [Abstract][Full Text] [Related]
17. TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study.
Yuan Y; He W; Yang Z; Qiu J; Huang Z; Shi Y; Lin Z; Zheng Y; Chen M; Lau WY; Li B; Yuan Y
Int J Surg; 2023 May; 109(5):1222-1230. PubMed ID: 37026861
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of HAIC (FOLFOX) combined with lenvatinib plus PD-1 inhibitors vs. TACE combined with lenvatinib plus PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas.
Lin Z; Chen D; Hu X; Huang D; Chen Y; Zhang J; Li X; Zou X
Am J Cancer Res; 2023; 13(11):5455-5465. PubMed ID: 38058801
[TBL] [Abstract][Full Text] [Related]
19. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases.
Ando E; Tanaka M; Yamashita F; Kuromatsu R; Yutani S; Fukumori K; Sumie S; Yano Y; Okuda K; Sata M
Cancer; 2002 Aug; 95(3):588-95. PubMed ID: 12209752
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis.
Kodama K; Kawaoka T; Aikata H; Uchikawa S; Nishida Y; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Kimura T; Nagata Y; Chayama K
Oncology; 2018; 94(4):215-222. PubMed ID: 29428943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
